Movymia (Teriparatide)

Teriparatide, the active ingredient in Movymia, is a parathyroid hormone analog presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture, and for increasing bone mass in patients with severe osteoporosis.

GNH USA supplies Movymia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movymia acts on the skeletal system to improve bone strength in patients with osteoporosis.

- Postmenopausal osteoporosis: increases bone mineral density and reduces fracture risk. - Male osteoporosis at high fracture risk: promotes bone formation and improves skeletal integrity. - Severe osteoporosis: enhances bone mass in patients with markedly low bone density.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient light‑headedness. - Leg cramps: muscle discomfort, often in the calves. - Injection‑site reactions: redness, swelling, or pain at the administration site. - Hypercalcemia: elevated blood calcium levels, usually mild.

Serious or Rare Side Effects: - Osteosarcoma: extremely rare malignant bone tumor. - Severe hypercalcemia: marked elevation of calcium requiring medical intervention. - Anaphylactic reactions: acute allergic response with airway compromise. - Hypotension: significant drop in blood pressure after injection. - Persistent bone pain: severe, lasting discomfort in the skeletal system.

Before initiating therapy, clinicians should evaluate calcium status, renal function, and prior skeletal malignancies.

- Assess serum calcium: correct abnormalities before use. - Monitor renal function: adjust therapy if impairment is present. - Review history of bone cancers: avoid in patients with prior osteosarcoma. - Caution in hyperparathyroidism: contraindicated. - Avoid concomitant high‑dose vitamin D or calcium supplements without monitoring. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Teriparatide may interact with agents that affect calcium homeostasis.

Major Interactions (Avoid): - High‑dose calcium supplements: can exacerbate hypercalcemia. - Vitamin D analogues (calcitriol): increase risk of elevated calcium levels.

Moderate Interactions (Monitor Closely): - Loop diuretics: may potentiate calcium loss, requiring monitoring. - Thiazide diuretics: can raise calcium levels, necessitating periodic checks. - Glucocorticoids: may blunt anabolic response, warranting efficacy assessment.